16.06.2025

New consortium agreement involving Proacta SA – working together for early diagnosis of cervical cancer

On June 13, 2025, an agreement was signed between Proacta SA, acting in a consortium with Euvic SA based in Gliwice (Consortium Leader), and the University Center for Women's and Newborn Health of the Medical University of Warsaw sp. z o.o. (“Ordering Party”) based in Warsaw.

The subject of the agreement is the implementation of the project entitled:

“Ultra-early detection of precancerous and cancerous changes in digital colposcopy using artificial intelligence – an opportunity to improve prognosis and increase survival rates for patients with cervical cancer”, financed by the National Recovery and Resilience Plan.

The scope of supplies and works includes:

• 20 research stations (10 notebooks and 10 workstations),
• licenses and access to cloud computing,
• licenses and access to a medical data analysis platform,
• licenses for intelligent diagnostic assistant software,
• design, delivery, and implementation of a Central Information System (CSI) with full transfer of copyrights and source codes.

The agreement will be implemented by March 31, 2026, i.e., within 270 days of its signing, and its total value is PLN 6,826,500.00 gross, of which as much as 98% will go to Proacta S.A.

This is another important step in the development of artificial intelligence-based solutions in medical diagnostics – this time in an area that is crucial for women's health.